Location History:
- Dublin, IE (1986 - 1988)
- Whale Bay, BM (1987 - 1988)
- Athlone, IE (1986 - 1990)
- Tuckerstown, BN (1994)
- Tuckerstown, BM (1989 - 1997)
Company Filing History:
20 out of 67 
1 out of 1 
1 out of 1 Years Active: 1986-1997
Title: Inventor Donald E. Panoz: A Pioneer in Controlled Drug Delivery
Introduction
Donald E. Panoz, based in Tuckerstown, Bermuda, is an accomplished inventor with a remarkable portfolio of 22 patents. His innovative contributions primarily lie in the field of pharmaceuticals, specifically in drug formulation technologies aimed at enhancing therapeutic efficacy and patient compliance.
Latest Patents
One of his most notable inventions is a controlled absorption diltiazem formulation designed for once-daily administration. This advanced formulation comprises a core of diltiazem or its pharmaceutically acceptable salts mixed with an organic acid. The core is enveloped in a multi-layer membrane that includes a significant portion of a water-insoluble synthetic polymer and a smaller proportion of a water-soluble synthetic polymer. The unique design of the membrane, which includes a carefully calibrated number of layers, facilitates a controlled release of diltiazem over a 24-hour period, ensuring optimal absorption following oral administration.
Career Highlights
Throughout his career, Panoz has significantly contributed to the pharmaceutical industry through his work with Elan Corporation, Plc, and 501 Elan Corporation Plc. His inventive spirit and dedication to improving drug delivery systems have established him as a prominent figure in the field.
Collaborations
Panoz has collaborated with many talented individuals during his journey as an inventor. Notably, Edward J. Geoghegan and Seamus Mulligan have been key collaborators, sharing insights and expertise that have undoubtedly influenced his innovative work.
Conclusion
Donald E. Panoz's impact on the pharmaceutical industry cannot be overstated. His dedication to creating groundbreaking inventions, such as controlled absorption formulations, continues to benefit patients by improving the delivery and effectiveness of essential medications. Through his patents and collaborations, he sets a commendable example for future innovators in the field.